Spurring Novel Technology Development and Adoption
In the Fred Hutch Innovation Lab, we are leading the in-house development and early adoption of powerful new research technologies that hold the potential to drive lifesaving discoveries in cancer immunology and other areas of science.
Our Areas of Focus
Unlocking Secrets of Cell Activity
We are introducing technologies for spatial analysis of single-cell transcription profiling, giving scientists unprecedented insights into cells’ inner workings.
Profiling the Immune System
We are increasing the availability of genetic data and analysis that makes information about the immune system more accessible to all scientists.
Driving Technological Innovation
We are discovering, testing and bringing new technologies online, targeting those of greatest utility for scientists at the vanguard of the promising field of immuno-oncology.
Our Facilities and Technology Pipeline
Our lab is one of the hallmarks of Fred Hutch’s Steam Plant building, a historic landmark newly redeveloped into a one-of-a-kind facility dedicated to spurring innovation at the nexus of data science and immunology.
There, we use a three-stage pipeline to develop novel technologies for use by the scientific community. First, we test, compare, advance and tailor new technologies that our Advisory Board has selected for their potential to facilitate the next discoveries in immunotherapy. Then, we work with selected researchers to evaluate the technology as they harness it to advance their early-stage research projects. Finally, we make that technology and the protocols and procedures we’ve developed available to researchers across the Hutch to accelerate their science.
Scientific Director
Dr. Evan Newell
Dr. Newell became the scientific director of the Fred Hutch Innovation Lab (FHIL) in January of 2022. He is an immunologist who develops and employs new technologies for accurately identifying specific biological signatures of human health and disease, including cancer and infectious diseases. He and his team work with blood and tissue samples, using mass cytometry and other single-cell analysis methods to better understand how the specificities of immune T cells influence their roles in clinically-productive responses against pathogens or cancers.
Advisory Board
Dr. Phil Bradley
Dr. Bradley is a computational biologist who studies the 3-D structures of proteins, develops software to predict how a protein works by interacting with specific RNA and DNA sequences, and is designing proteins that might be used to make therapies work even better.
Dr. Lillian Cohn
Dr. Cohn is an immunologist who uses advanced techniques to study latent HIV infections, aiming to find ways to stop the expansion and reactivation of latently infected cells, and thereby effectively cure HIV disease.
Dr. Marion Dorer
Dr. Dorer is the Vice President of Fred Hutch's Research Administration. Research Administration accelerates innovative discoveries at Fred Hutch by enabling scientific collaboration, providing opportunities and funding for enhanced cross-disciplinary interactions, making the latest technology available, and providing center-wide administrative support to our faculty and their teams.
Dr. Scott Furlan
Dr. Furlan studies the biology of blood stem cell transplantation and cellular immunotherapy, employing a method called single-cell genomics to reveal how critical immune cells respond during these treatments and how the therapies might be further improved.
Dr. Lawrence Fong
Dr. Lawrence (Larry) Fong researches the mechanisms of response and resistance to cancer immunotherapies in both preclinical models and in cancer patients. A physician-scientist, his work helped lead to approval by the U.S. Food and Drug Administration (FDA) of sipuleucel-T, an immunotherapy for prostate cancer.
Dr. Geoffrey Hill
Dr. Hill is a physician-scientist who specializes in blood stem cell transplantation. He is one of the top authorities on the transplant complication known as graft-vs.-host disease, or GVHD.
Dr. Gordon Roble
Dr. Roble is the Associate Vice President of Fred Hutch’s Shared Resources, directing more than a dozen core facilities. These cores help drive advances by integrating dedicated experts and sophisticated technologies across the entire research pipeline, from basic science to clinical trials.
